News
EQS-News: Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination
EQS-News: Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
EQS-News: Formycon included in TecDAX Index of Deutsche Börse
Newron and Myung In Pharm Announce License Agreement for evenamide in South Korea
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous
Sonova announces changes to its Board of Directors
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals
EQS-News: Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical
Humana Earns Equality 100 Award in Human Rights Campaign Foundation’s 2025 Corporate Equality Index
Leading health insurer and health care services company Humana Inc. (NYSE: HUM), has earned a score of 100 on the Human Rights Campaign Foundation (HRCF) Corporate Equality Index (CEI) for the 11th
Chemed Corporation to Present at the 43rd Annual JPMorgan Healthcare Conference
Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 43rd Annual JPMorgan Healthcare Conference on Tuesday, January 14, 2024, at approximately 10:30 a.m. PST at
Acadia Healthcare to Participate in 43rd Annual J.P. Morgan Healthcare Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, January 13-16, 2025, in San Francisco
Premier, Inc. to Participate in J.P. Morgan Healthcare Conference on January 14, 2025
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in the J.P. Morgan Healthcare
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025.
The live presentation
Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025.
Bernard Zovighian, chief executive officer, is
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 43rd Annual J.P
EQS-News: Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 43rd Annual J.P
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL